查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1236058

多發性硬化症治療全球市場規模研究與預測：按藥物類別、給藥途徑、分銷渠道和地區分析，2022-2029 年

Global Multiple Sclerosis Drugs Market Size study & Forecast, by Drug Class by Route of Administration, by Distribution Channel and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

多發性硬化症是一種炎症性免疫介導的疾病，會影響大腦和脊髓中的神經元，導致軸突切斷、脫髓鞘和神經變性。

最常用的治療方法包括物理療法、肌肉鬆弛劑、抗抑鬱藥、口服藥物、注射劑和靜脈注射。 這些包括富馬酸二甲酯、特立氟胺和克拉曲濱等口服藥物，ocrelizumab 等輸液療法，以及肌肉或皮下注射的干擾素-BETA 和醋酸格拉替雷等注射療法。 市場增長的主要驅動力是多發性硬化症患病率上升和市場開發研發投資增加，預計這將在預測期內支持市場增長。

根據多發性硬化症國際聯合會 (MSIF) 的數據，全球多發性硬化症患者人數將從 2013 年的 230 萬增加到 2020 年的 280 萬。 隨著該病患病率的增加，全世界對多發性硬化症有效診斷和治療的需求不斷增加。 此外，市場參與者增加研發和臨床試驗也有望為市場創造有利的需求。 例如，賽諾菲正在進行trebrutinib（PPMS）治療非複發性繼發進展性多發性硬化症（nrSPMS）、復發性多發性硬化症（RMS）和原發性進展性多發性硬化症的三期臨床試驗。 賽諾菲預計將分別在 2024 年和 2025 年提交該藥物用於其批准的適應症。 此外，預計政府對多發性硬化症治療的支持增加將在預測期內推動市場增長。 然而，多發性硬化症治療的高成本將阻礙整個 2022-2029 年預測期內的市場增長。

多發性硬化症治療藥物全球市場研究考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於研發投入增加、新產品開發以及對免疫抑製劑和分子抗體藥物的需求不斷增長，北美已成為全球市場份額的領導者。 另一方面，由於多發性硬化症患病率增加以及多個國家政府加大力度降低治療費用等因素，亞太地區在預測期內將出現高增長率。預計將顯示

市場近期發展

  • 2021 年 3 月，Janssen Pharmaceuticals 獲得美國 FDA 批准 Ponvory，這是一種口服特異性 1-磷酸鞘氨醇受體 1 (S1P1) 調節劑，用於治療復發性 MS 患者。澄清。 與Aubagio相比，Ponvory在降低年復發率方面更有效。 通過將該產品添加到其產品組合中，該公司擴大了其治療 MS 的產品系列。

全球市場報告範圍

  • 歷史數據：2019-2020-2021
  • 估算基準年：2021 年
  • 預測期：2022-2029
  • 報告範圍：收入預測、公司排名、競爭格局、增長因素、趨勢
  • 按地區劃分：北美、歐洲、亞太地區、拉丁美洲、世界其他地區
  • 定制範圍：免費報告定制（最多 8 個工作小時）。 按國家、地區和部門劃分的範圍的添加和更改。

本研究的目的是弄清近年來各個領域和國家的市場規模，並對未來幾年的市場規模進行預測。 該報告旨在捕捉被調查國家工業的定性和定量方面的情況。

它還提供了關鍵方面的詳細信息，例如決定市場未來增長的驅動因素和挑戰。 此外，它還結合了利益相關者投資的潛在微觀市場機會，以及主要參與者的競爭格局等詳細分析。

內容

第 1 章執行摘要

  • 市場概況
  • 2019-2029 年各細分市場的全球市場估計和預測
    • 多發性硬化症治療市場，按地區劃分，2019-2029 年
    • 多發性硬化症治療市場，按藥物類別，2019-2029 年
    • 按給藥途徑劃分的多發性硬化症藥物市場，2019-2029 年
    • 多發性硬化症治療市場，按分銷渠道，2019-2029 年
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第 2 章。全球多發性硬化症治療市場的定義和範圍

  • 調查目的
  • 市場定義和範圍
    • 調查範圍
    • 工業發展
  • 調查年份
  • 貨幣兌換率

第 3 章多發性硬化症藥物的全球市場動態

  • 多發性硬化症藥物市場影響分析 (2019-2029)
    • 市場驅動力
      • 多發性硬化症患病率上升
      • 增加研發投資
    • 市場挑戰
      • 多發性硬化症藥物價格上漲
    • 市場機會
      • 政府對多發性硬化症治療的支持越來越多

第 4 章多發性硬化症藥物全球市場行業分析

  • 波特 5 力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法 (2019-2029)
  • 害蟲分析
    • 政治
    • 經濟的
    • 社交
    • 技術
  • 最佳投資機會
  • 關鍵成功策略
  • 業內人士的前景
  • 分析師的建議和結論

第 5 章風險評估 COVID-19 影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

第 6 章。多發性硬化症藥物的全球市場：按藥物類別分類

  • 市場概況
  • 多發性硬化症治療藥物的全球市場：按藥物類別、性能潛力分析
  • 2019-2029 年按藥物類別劃分的多發性硬化症藥物全球市場估計和預測
  • 多發性硬化症藥物市場細分分析
    • 免疫調節劑
    • 免疫抑製劑
    • 干擾素

第 7 章。多發性硬化症藥物的全球市場：按給藥途徑分類

  • 市場概況
  • 多發性硬化症藥物的全球市場：按給藥途徑進行的性能潛力分析
  • 2019-2029 年多發性硬化症藥物全球市場估計和預測（按給藥途徑）
  • 多發性硬化症藥物市場細分分析
    • 口語
    • 注射

第 8 章。全球多發性硬化症藥物市場：按分銷渠道分類

  • 市場概況
  • 多發性硬化症藥物的全球市場：按分銷渠道進行的性能潛力分析
  • 2019-2029 年多發性硬化症藥物全球市場估計和預測（按分銷渠道）
  • 多發性硬化症藥物市場細分分析
    • 醫院藥房
    • 零售藥房
    • 在線藥店

第 9 章。多發性硬化症藥物的全球市場：區域分析

  • 多發性硬化症藥物市場，按地區劃分的市場概況
  • 北美
    • 美國
      • 2019-2029 年按藥物類別的估計和預測
      • 按給藥途徑估算和預測，2019-2029 年
      • 2019-2029 年各分銷渠道的估計和預測
    • 加拿大
  • 歐洲多發性硬化症藥物市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲
  • 亞太地區多發性硬化症藥物市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲多發性硬化症藥物市場概況
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 世界其他地方

第 10 章衝突信息

  • 頂級市場策略
  • 公司簡介
    • 百健公司
      • 關鍵信息
      • 概覽
      • 財務（僅當數據可用時）
      • 產品概覽
      • 近期趨勢
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Janssen Pharmaceuticals, Inc.（Johnson & Johnson Corporation）
    • Bristol-Myers Squibb Company
    • Cipla Inc.

第 11 章研究過程

  • 研究過程
    • 數據挖掘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 調查的特點
  • 調查先決條件

Global Multiple Sclerosis Drugs Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2022-2029. Multiple sclerosis is an inflammatory immune-mediated disorder that affects nerve cells in the brain and the spinal cord, causing axonal transection, demyelination, and neurodegeneration. Some of the most often used treatments include physical therapy, muscle relaxants, antidepressants, and oral, injectable, and infused medications. Oral drugs including dimethyl fumarate, teriflunomide, and cladribine; intravenous infusion therapies like ocrelizumab; and injectable therapies like interferon-beta, glatiramer acetate, given intramuscularly or subcutaneously. The key factor driving the market growth is rising prevalence of Multiple Sclerosis disease and rising R&D investment by the market players for the drugs development that anticipated to support the market growth during forecast period.

According to the Multiple Sclerosis International Federation (MSIF), the number of patients with multiple sclerosis throughout the globe increased from 2.3 million in 2013 to 2.8 million in 2020. The demand for effective multiple sclerosis diagnosis and treatment has increased worldwide as a result of the disease's rising prevalence. Also, the rising R&D and clinical trial by the market players will create the lucrative demand for the market. For instance, For the therapy of non-relapsing secondary progressive MS (nrSPMS), relapsing forms of MS (RMS), and primary progressive MS, Sanofi is conducting a phase III clinical trial for tolebrutinib (PPMS). Sanofi anticipates submitting this medication in 2024 and 2025+, respectively, for the approved indications. Additionally, the rising government support for the treatment of multiple sclerosis is likely to increase the market growth during the forecast period. However, the high cost of Multiple Sclerosis Drugs stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Multiple Sclerosis Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the rising R&D investment, new product development, and growing demand for immunosuppressant and molecular antibody drugs. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as growing prevalence of multiple sclerosis disease and rising government initiatives in several countries to reduce the cost of treatment would create lucrative growth prospects for the Multiple Sclerosis Drugs market across Asia Pacific region.

Major market players included in this report are:

  • Biogen Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
  • Bristol-Myers Squibb Company
  • Cipla Inc.

Recent Developments in the Market:

  • In March 2021, Janssen Pharmaceutical, Inc. revealed the U.S. FDA approval of Ponvory, an oral specific sphingosine-1-phosphate receptor 1 (S1P1) modulator to treat people with relapsing forms of MS. In comparison to Aubagio, Ponvory is more effective at lowering annual relapse rates. The company increased its range of products for the treatment of MS with the inclusion of this product in its portfolio.

Global Multiple Sclerosis Drugs Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Drug Class, Route of Administration, Distribution Channel, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

  • Immunomodulators
  • Immunosuppressants
  • Interferons

By Route of Administration:

  • Oral
  • Injection

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Multiple Sclerosis Drugs Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Multiple Sclerosis Drugs Market, by Drug Class, 2019-2029 (USD Billion)
    • 1.2.3. Multiple Sclerosis Drugs Market, by Route of Administration, 2019-2029 (USD Billion)
    • 1.2.4. Multiple Sclerosis Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Multiple Sclerosis Drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Multiple Sclerosis Drugs Market Dynamics

  • 3.1. Multiple Sclerosis Drugs Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of multiple sclerosis disease
      • 3.1.1.2. Growing R&D Investment
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of multiple sclerosis drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising government support for the treatment of multiple sclerosis

Chapter 4. Global Multiple Sclerosis Drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Multiple Sclerosis Drugs Market, by Drug Class

  • 6.1. Market Snapshot
  • 6.2. Global Multiple Sclerosis Drugs Market by Drug Class, Performance - Potential Analysis
  • 6.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
  • 6.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
    • 6.4.1. Immunomodulators
    • 6.4.2. Immunosuppressants
    • 6.4.3. Interferons

Chapter 7. Global Multiple Sclerosis Drugs Market, by Route of Administration

  • 7.1. Market Snapshot
  • 7.2. Global Multiple Sclerosis Drugs Market by Route of Administration, Performance - Potential Analysis
  • 7.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
  • 7.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
    • 7.4.1. Oral
    • 7.4.2. Injection

Chapter 8. Global Multiple Sclerosis Drugs Market, by Distribution Channel

  • 8.1. Market Snapshot
  • 8.2. Global Multiple Sclerosis Drugs Market by Distribution Channel, Performance - Potential Analysis
  • 8.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 8.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy

Chapter 9. Global Multiple Sclerosis Drugs Market, Regional Analysis

  • 9.1. Multiple Sclerosis Drugs Market, Regional Market Snapshot
  • 9.2. North America Multiple Sclerosis Drugs Market
    • 9.2.1. U.S. Multiple Sclerosis Drugs Market
      • 9.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Multiple Sclerosis Drugs Market
  • 9.3. Europe Multiple Sclerosis Drugs Market Snapshot
    • 9.3.1. U.K. Multiple Sclerosis Drugs Market
    • 9.3.2. Germany Multiple Sclerosis Drugs Market
    • 9.3.3. France Multiple Sclerosis Drugs Market
    • 9.3.4. Spain Multiple Sclerosis Drugs Market
    • 9.3.5. Italy Multiple Sclerosis Drugs Market
    • 9.3.6. Rest of Europe Multiple Sclerosis Drugs Market
  • 9.4. Asia-Pacific Multiple Sclerosis Drugs Market Snapshot
    • 9.4.1. China Multiple Sclerosis Drugs Market
    • 9.4.2. India Multiple Sclerosis Drugs Market
    • 9.4.3. Japan Multiple Sclerosis Drugs Market
    • 9.4.4. Australia Multiple Sclerosis Drugs Market
    • 9.4.5. South Korea Multiple Sclerosis Drugs Market
    • 9.4.6. Rest of Asia Pacific Multiple Sclerosis Drugs Market
  • 9.5. Latin America Multiple Sclerosis Drugs Market Snapshot
    • 9.5.1. Brazil Multiple Sclerosis Drugs Market
    • 9.5.2. Mexico Multiple Sclerosis Drugs Market
    • 9.5.3. Rest of Latin America Multiple Sclerosis Drugs Market
  • 9.6. Rest of The World Multiple Sclerosis Drugs Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Biogen Inc.
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Pfizer Inc.
    • 10.2.3. F. Hoffmann-La Roche Ltd.
    • 10.2.4. Novartis AG
    • 10.2.5. Merck & Co., Inc.
    • 10.2.6. Sanofi S.A.
    • 10.2.7. Teva Pharmaceutical Industries Ltd.
    • 10.2.8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
    • 10.2.9. Bristol-Myers Squibb Company
    • 10.2.10. Cipla Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Multiple Sclerosis Drugs Market, report scope
  • TABLE 2. Global Multiple Sclerosis Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Multiple Sclerosis Drugs Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
  • TABLE 4. Global Multiple Sclerosis Drugs Market estimates & forecasts by Route of Administration 2019-2029 (USD Billion)
  • TABLE 5. Global Multiple Sclerosis Drugs Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 6. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 17. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 20. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 23. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 26. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 29. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 32. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 35. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 38. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 41. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 44. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 47. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 50. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 53. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 59. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 62. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 65. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 68. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Multiple Sclerosis Drugs Market
  • TABLE 71. List of primary sources, used in the study of global Multiple Sclerosis Drugs Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Multiple Sclerosis Drugs Market, research methodology
  • FIG 2. Global Multiple Sclerosis Drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Multiple Sclerosis Drugs Market, key trends 2021
  • FIG 5. Global Multiple Sclerosis Drugs Market, growth prospects 2022-2029
  • FIG 6. Global Multiple Sclerosis Drugs Market, porters 5 force model
  • FIG 7. Global Multiple Sclerosis Drugs Market, pest analysis
  • FIG 8. Global Multiple Sclerosis Drugs Market, value chain analysis
  • FIG 9. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Multiple Sclerosis Drugs Market, regional snapshot 2019 & 2029
  • FIG 15. North America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Multiple Sclerosis Drugs Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable